Regensburg-based start-up solves the bioavailability problem faced by many dietary supplements
EVANIUM secures €2.2 million in seed funding for its bioavailability technology
EVANIUM has successfully completed a funding round with investors including FoodLabs from Berlin and Feast Ventures from Munich. The capital will be used to further develop its technology platform for increasing bioavailability, a key challenge for many dietary supplements. The funds will be used to accelerate clinical validation, portfolio expansion, and international market growth.
EVANIUM Healthcare GmbH was founded in 2019 at BioPark Regensburg, an enterprise owned by the city of Regensburg, and has developed a process for improving the solubility of secondary plant compounds. This process significantly increases the stability and bioavailability of ingredients for use in dietary supplements, functional foods, nutricosmetics, and pharmaceuticals. The process, called OPTISOLV®, is patented and protected by intellectual property rights. EVANIUM was founded by a multidisciplinary team with backgrounds in pharmaceuticals and entrepreneurship and has rapidly evolved from a research and development-oriented start-up to a technology partner for established companies, currently employing 12 people. In 2026 alone, the young company produced and shipped more than two tons of material, demonstrating its industrial maturity.
Despite high prices, many dietary supplements deliver only a fraction of their promised effects because a large proportion of the active ingredients are poorly absorbed by the body. OPTISOLV® technology can improve this. The process utilizes a dual-coating system that combines a cyclodextrin-based core with an outer phospholipid shell. This stabilizes natural active ingredients in a crystal-free, highly dispersible state. This structure prevents agglomeration, improves permeability, and enables significantly higher solubility and absorption – all using only natural substances. For complex active ingredients like curcumin, solubility increases by over 1,000-fold compared to the native form, while release during digestion is improved by more than 170-fold. This allows OPTISOLV® to outperform conventional phospholipid-based approaches in direct comparative tests.
In 2025, the company, together with Hevert Arzneimittel GmbH & Co. KG successfully launched OPTISOLV® Curcumin. Preparations are currently underway for clinical trials to further strengthen the scientific evidence supporting the efficacy of EVANIUM formulations.
Other news from the department business & finance
Most read news
More news from our other portals
Something is happening in the food & beverage industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.